TNFSF13B and IgA glomerulonephritis: Calculations of the human equivalent dose, adjusted for the ~5-7-fold reduced potency of povetacicept for mouse BAFF and APRIL in vitro (15), predict that the dosing regimen used in the EAMG mouse model is roughly equivalent to 90 mg every 4 weeks in humans, which is similar to the 80 mg every 4 weeks dose regimen being evaluated in the ongoing Phase 3 trial in IgA nephropathy (NCT06564142).